Cannabis Science Announces an Overwhelming Response to its Groundbreaking Research on the Use of Cannabinoids in the Treatment of Cancers, Already Has More Views Than 91% of the Papers Published in all Frontiers Journals

0
55

Cannabis Science, Inc. (OTC: CBIS), a U.S. company specializing in the development of cannabinoid-based medicines, is pleased to report very strong interest among researchers in the Company’s groundbreaking work to investigate the use of cannabinoids in the treatment of cancers. Cannabis Science’s recent, peer-reviewed publication in Frontiers in Oncology, “Nanoparticle Drones to Target Lung Cancer with Radiosensitizers and Cannabinoids”, in just a few months, has already been viewed more than 6,500 times, with the article having more views than 91% of the papers published in all Frontiers journals.

The publication can be accessed at:

https://www.frontiersin.org/articles/10.3389/fonc.2017.00208/full

“We believe that this noticeable interest in our work reflects the fact that we have broken new ground in the use of cannabinoids in cancer therapeutics and novel ways of drug delivery and targeting,” stated Dr. Allen Herman, Chief Medical Officer of Cannabis Science. “This proof-of-concept paper describes a novel delivery mechanism for cannabinoids in the treatment of cancer.”

“Cannabis Science’s current research forms part of a pipeline from research to scientific publication that CBIS is developing with its research partners, and demonstrates the Company’s strong commitment to science in its pharmaceutical development program. We developed this pipeline to ensure that Cannabis Science’s research work reaches the scientific community and the public in a timely fashion. Critical aspects of the success of collaborative work are the administrators, clinicians, laboratory scientists, and information experts that form our research family,” stated Mr. Raymond C. Dabney, President and CEO of CBIS.

“Currently our funded research focuses on the clinical applications of cannabinoids in cancer treatment and pain management, but we will expand our portfolio in the following significant directions: (a) we will investigate the effectiveness of cannabinoid treatment in an increasing array of cancers, especially difficult to treat cancers and those with high fatality rates, (b) we will develop novel targeted delivery methods in the use of cannabinoids, and (c) we will, with advances in bioinformatics, computer science, and pharmacology, explore the mechanisms of action of cannabinoids in the management of disease,” stated Dr. Herman.

About Cannabis Science, Inc.


Cannabis Science, Inc. takes advantage of its unique understanding of metabolic processes to provide novel treatment approaches to a number of illnesses for which current treatments and understanding remain unsatisfactory. Cannabinoids have an extensive history dating back thousands of years, and currently, there are a growing number of peer-reviewed scientific publications that document the underlying biochemical pathways that cannabinoids modulate. The Company works with leading experts in drug development, medicinal characterization, and clinical research to develop, produce, and commercialize novel therapeutic approaches for the treatment for illnesses caused by infections as well as for age-related illness. Our initial focus is on cancers, HIV/AIDS, and neurological conditions. The Company is proceeding with the research and development of its proprietary drugs as a part of this initial focus: CS-S/BCC-1, CS-TATI-1, and CS-NEURO-1, respectively.

Forward-Looking Statements


This Press Release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934. A statement containing words such as “anticipate,” “seek,” intend,” “believe,” “estimate,” “expect,” “project,” “plan,” or similar phrases may be deemed “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Some or all of the events or results anticipated by these forward-looking statements may not occur. Factors that could cause or contribute to such differences include the future U.S. and global economies, the impact of competition, and the Company’s reliance on existing regulations regarding the use and development of cannabis-based drugs. Cannabis Science, Inc., does not undertake any duty nor does it intend to update the results of these forward-looking statements. Safe Harbor Statement. The Private Securities Litigation Reform Act of 1995 provides a ‘safe harbor’ for forward looking statements. Certain of the statements contained herein, which are not historical facts are forward looking statements with respect to events, the occurrence of which involved risks and uncertainties. These forward-looking statements may be impacted, either positively or negatively, by various factors. Information concerning potential factors that could affect the company is detailed from time to time in the company’s reports filed with the Securities and Exchange Commission.

Contact Information

Cannabis Science, Inc.
Dr. Allen Herman
Chief Medical Officer
allen.herman@cannabisscience.com
Tel: 1-888-263-0832

Cannabis Science, Inc.
Mr. Raymond C. Dabney
President & CEO, Co-Founder
raymond.dabney@cannabisscience.com
Tel: 1-888-263-0832

NO COMMENTS

LEAVE A REPLY